<- Go Home
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc engages in research, development, and subsequent manufacture and commercialisation of cell therapies to treat cancer in the United States and the United Kingdom. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Market Cap
$6.8M
Volume
31.1M
Cash and Equivalents
$26.0M
EBITDA
-$57.5M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$5.9M
Profit Margin
100.00%
52 Week High
$0.28
52 Week Low
$0.00
Dividend
N/A
Price / Book Value
0.21
Price / Earnings
-0.09
Price / Tangible Book Value
0.21
Enterprise Value
-$5.1M
Enterprise Value / EBITDA
0.10
Operating Income
-$64.1M
Return on Equity
346.65%
Return on Assets
-25.87
Cash and Short Term Investments
$26.0M
Debt
$14.1M
Equity
$32.0M
Revenue
$5.9M
Unlevered FCF
-$57.1M
Sector
Biotechnology
Category
N/A